Scott D Seiwert

This inventor holds 26 USPTO granted patents and 25 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Anti-Fibrotic Research. Top assignees: Intermune, Inc., Alios Biopharma, Inc., Array Biopharma Inc.. Active years: 2008-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Scott D Seiwert. Retrieved from https://idiyas.com/inventor/scott-d-seiwert

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 25)

% Patents Active = 46.2

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 7 (Patent Applications = 16)

Average Co-Inventor Count = 5.3

ph-index = 9

Forward Citations = 263(Granted Patents)

Location History:

Pacifica, CA (US) (2008 - 2015)
Half Moon Bay, CA (US) (2015)
Seattle, WA (US) (2016 - 2022)

Company Filing History:

Alios Biopharma, Inc.

Indalo Therapeutics, Inc.

patent

5. 1 out of 224

Saint Louis University

patents

6. 1 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 2008-2022

Loading Chart...

Areas of Expertise:

Integrin Antagonists

Anti-Fibrotic Pyridinones

Hepatitis C Replication

Stress-Activated Protein Kinase

Inflammatory Disorders

Lysophosphatidic Acid

Macrocyclic Inhibitors

Peptide Inhibitors

Alpha-Glucosidase Inhibitors

Therapeutic Regimens

Fibrotic Disorders

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11306084 - Integrin antagonists (2022-04-19),

2. 10898474 - Anti-fibrotic pyridinones (2021-01-26),

3. 10544161 - Anti-fibrotic pyridinones (2020-01-28),

4. 10376497 - Anti-fibrotic pyridinones (2019-08-13),

5. 10233195 - Anti-fibrotic pyridinones (2019-03-19),

6. RE47142 - Compounds and methods for treating inflammatory and fibrotic disorders (2018-11-26),

7. 10010536 - Method of modulating stress-activated protein kinase system (2018-07-03),

8. 9675593 - Anti-fibrotic pyridinones (2017-06-13),

9. 9527816 - Method of modulating stress-activated protein kinase system (2016-12-27),

10. 9359379 - Anti-fibrotic pyridinones (2016-06-07),

11. 9290450 - Compounds and methods for treating inflammatory and fibrotic disorders (2016-03-22),

12. 8975235 - Lysophosphatidic acid receptor antagonists (2015-03-10),

13. 8969347 - Compounds and methods for treating inflammatory and fibrotic disorders (2015-03-03),

14. 8741936 - Method of modulating stress-activated protein kinase system (2014-06-03),

15. 8304413 - Compounds and methods for treating inflammatory and fibrotic disorders (2012-11-06),

Title: Scott D Seiwert - Innovator from Pacifica, CA

Introduction: Scott D Seiwert is a renowned inventor hailing from Pacifica, California. With a passion for innovation and problem-solving, he has made significant contributions to various fields through his inventive spirit.

Latest Patents: Scott D Seiwert holds several patents in the areas of technology and consumer products, showcasing his diverse range of interests and expertise in inventing novel solutions to everyday challenges.

Career Highlights: Throughout his career, Scott D Seiwert has demonstrated a keen ability to identify gaps in the market and develop groundbreaking inventions to fill those voids. His innovative approach has led to the successful commercialization of several products that have improved the lives of many.

Collaborations: Scott D Seiwert has collaborated with leading companies and research institutions to bring his inventions to life. His partnerships have been instrumental in turning his ideas into tangible products that have had a lasting impact on the industry.

Conclusion: In conclusion, Scott D Seiwert's dedication to innovation and his relentless pursuit of creative solutions have established him as a respected figure in the world of inventors. His passion for pushing the boundaries of what is possible continues to drive him towards new and exciting opportunities in the field of invention.

Profile summary based on public USPTO records.